Billionaire Steve Cohen’s Point72 Reports 6.5% Stake In Celator Pharmaceuticals Inc (CPXX) Amid 500% Jump

As a new filing with the Securities and Exchange Commission showed, billionaire Steve Cohen‘s Point72 Asset Management has initiated a stake in Celator Pharmaceuticals Inc (NASDAQ:CPXX) amid a 500% jump registered by the stock. The 13G filing showed that Point72 currently owns almost 2.26 million shares of Celator, which represent 6.5% of the company’s outstanding stock.

Celator’s stock surged after the company announced positive results from the Phase 3 trial of its drug candidate in patients with blood cancer. Overall, the median survival for patients treated with Celator’s VYXEOS was 9.56 months, versus 5.96 months for patients treated with standard care regimen, known as 7+3. Celator plans to submit submit its New Drug Application later this year.

You can access the original SEC filing by clicking here.

Ownership Summary Table

Name Sole Voting Power Shared Voting Power Sole Dispositive Power Shared Dispositive Power Aggregate Amount Owned Power Percent of Class
Point7 0 2,255,000 0 2,255,000 2,255,000 6.5%
Point7 0 2,255,000 0 2,255,000 2,255,000 6.5%
EverPoint Asset Management 0 600,000 0 600,000 600,000 1.7%
Steven A. Cohen 0 2,855,000 0 2,855,000 2,855,000 8.3%
Steve Cohen
Steve Cohen
Point72 Asset Management

Page 1 of 9 SEC Filing

Washington, D.C. 20549
Under the Securities Exchange Act of 1934
(Amendment No. )*


(Name of Issuer)

Common Stock, Par Value $0.001 Per Share

(Title of Class of Securities)
(CUSIP Number)
March 14, 2016
(Date of Event which Requires Filing
of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)
*The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.
The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).
Follow Celator Pharmaceuticals Inc (NASDAQ:NONE)